Rapid Response: The promise and peril of engineering biology, w/Ginkgo Bioworks Reshma Shetty
Masters of Scale20 Okt 2022

Rapid Response: The promise and peril of engineering biology, w/Ginkgo Bioworks Reshma Shetty

Moderna's Covid-19 vaccine would not have scaled without Ginkgo Bioworks. Reshma Shetty, co-founder and COO of Ginkgo – slated to go public via SPAC acquisition at a reported $15 billion valuation – explains how biotech innovation can build a better future now. Ginkgo's platform already serves industries from food and agriculture, to materials, to healthcare. Shetty acknowledges that engineering genes is a high stakes pursuit, and says Ginkgo is trying to pair the ambition of Silicon Valley with a "higher level of care" than consumer tech companies like social media have demonstrated. The key, Shetty says, is creating an unstable equilibrium – propelling progress but not at the expense of principles.

Read a transcript of this interview at: mastersofscale.com

Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Avsnitt(685)

Populärt inom Business & ekonomi

framgangspodden
rss-jossan-nina
badfluence
varvet
svd-tech-brief
rss-borsens-finest
rss-svart-marknad
uppgang-och-fall
avanzapodden
bathina-en-podcast
fill-or-kill
lastbilspodden
rss-inga-dumma-fragor-om-pengar
rss-dagen-med-di
tabberaset
borsmorgon
rss-kort-lang-analyspodden-fran-di
rikatillsammans-om-privatekonomi-rikedom-i-livet
24fragor
montrosepodden